Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) on Tuesday, soared 8.59% from the previous trading day, before settling in for the closing price of $312.11. Within the past 52 weeks, MDGL’s price has moved between $200.63 and $377.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -32.06%. The company achieved an average annual earnings per share of 52.20%. With a float of $20.08 million, this company’s outstanding shares have now reached $22.20 million.
The extent of productivity of a business whose workforce counts for 528 workers is very important to gauge. In terms of profitability, gross margin is 96.37%, operating margin of -60.09%, and the pretax margin is -54.68%.
Madrigal Pharmaceuticals Inc (MDGL) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Madrigal Pharmaceuticals Inc is 9.56%, while institutional ownership is 107.05%. The most recent insider transaction that took place on Jul 18 ’25, was worth 350,005. In this transaction Director of this company sold 1,000 shares at a rate of $350.00, taking the stock ownership to the 461,044 shares. Before that another transaction happened on Jul 18 ’25, when Company’s Director sold 1,400 for $350.03, making the entire transaction worth $490,044. This insider now owns 187,164 shares in total.
Madrigal Pharmaceuticals Inc (MDGL) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 52.20% per share during the next fiscal year.
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) Trading Performance Indicators
Madrigal Pharmaceuticals Inc (MDGL) is currently performing well based on its current performance indicators. A quick ratio of 4.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.85, a number that is poised to hit -2.57 in the next quarter and is forecasted to reach 4.29 in one year’s time.
Technical Analysis of Madrigal Pharmaceuticals Inc (MDGL)
The latest stats from [Madrigal Pharmaceuticals Inc, MDGL] show that its last 5-days average volume of 0.59 million was superior to 0.38 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 61.62%.
During the past 100 days, Madrigal Pharmaceuticals Inc’s (MDGL) raw stochastic average was set at 79.55%, which indicates a significant decrease from 80.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.47 in the past 14 days, which was higher than the 14.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $296.63, while its 200-day Moving Average is $308.06.
